Skip to content

Metabolic Syndrome and Obesity: Targets and Therapy

· 0 citations · 161 references

TL;DR

The evidence highlights the value of early intervention and targeting multiple risk factors with both lifestyle and pharmacological strategies to give the best chance of reducing macrovascular complications in the long term.

View source

Similar papers

Review Open access Sep 2026

Type 1 diabetes and cardiovascular medicine

There are an estimated 9.5 million people living with type 1 diabetes (T1D) globally, with cardiovascular disease (CVD) remaining a major cause of morbidity and mortality despite advances in care. Atherosclerosis occurs earlier in people with T1D and those with T1D-onset in early childhood are at particularly high life...

Alicia J. Jenkins, Michael L. H. Huang, Madeleine Hemphill et al. · 0 citations
Review Open access Aug 2026

Beyond glycemia: clinical nutrition in type 2 diabetes and cardiometabolic risk

Type 2 diabetes (T2D) is a multifactorial cardiometabolic disorder in which dysglycemia coexists with visceral adiposity, insulin resistance, atherogenic dyslipidemia, hypertension, and metabolic dysfunction-associated steatotic liver disease (MASLD). In this setting, clinical nutrition should be considered a therapeut...

A. M. Labate, P. Villari · 0 citations
Review Open access Aug 2026

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health.

Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a 'triple threat' with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stres...

A. Forrest, P. Majety, Stéphanie B. Mayer et al. · 0 citations
Review Open access Aug 2026

Targeting Dyslipidemia in Ischemic Stroke: Pathophysiology, Clinical Evidence, and Future Perspectives.

An overview of domestic and international guidelines for dyslipidemia is provided and the association between dyslipidemia and ischemic stroke is summarized from the perspectives of pathophysiology, pathological findings, and imaging and blood biomarker.

Junya Aoki · 0 citations
Review Open access Aug 2026

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence.

Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin-angiotensin-aldosterone s...

C. Antza, Andrej Belančić, Jens Jordan et al. · 0 citations
Open access Aug 2026

The Complex Interplay Between Dyslipidemic Subjects Living with Type 2 Diabetes and Metabolic Syndrome and Statin Treatment: A Reflection on Adherence and Persistence in the Real World

High levels of blood cholesterol are a major risk factor for atherosclerotic cardiovascular disease and require early and consistent utilization of statins as first-line medications to avoid disabling or even deadly consequences. Nevertheless, real-world treatment adherence is significantly lower than that reported in...

F. Strollo, G. Guarino, Ersilia Satta et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.